 HIV infection was associated with greater increases in focal carotid artery plaque over 7 years among both women and men, particularly among those with lower CD4+ counts.  Increased plaque was observed even among HIV-infected individuals with persistent virologic suppression. ABSTRACT Background: HIV-infected individuals live longer as a result of effective treatment, but long-term consequences of infection, treatment, and immunological dysfunction are poorly understood. Methods: We prospectively examined 1011 women (74% HIV-infected) in the Women's Interagency HIV Study and 811 men (65% HIV-infected) in the Multicenter AIDS Cohort Study who underwent repeated B-mode carotid artery ultrasound imaging in 2004-2013. Outcomes included changes in right common carotid artery intima-media thickness (CCA-IMT) and new focal carotid artery plaque formation (IMT >1.5 mm) over median 7 years. We assessed the association between HIV serostatus and progression of subclinical atherosclerosis, adjusting for demographic, behavioral, and cardiometabolic risk factors.
A c c e p t e d M a n u s c r i p t INTRODUCTION Survival among HIV-infected individuals has improved dramatically since the widespread availability of potent antiretroviral therapy (ART). [1, 2] However, at the same time, increased morbidity and mortality due to cardiovascular disease (CVD) has been reported. [3] [4] [5] Several factors may contribute to increased CVD risk among HIV-infected individuals, including high smoking rates; [6] pro-atherogenic dyslipidemia and other adverse effects of ART; [7, 8] or HIV infection itself through immune activation and inflammation. [9, 10] Also potentially influencing CVD risk are recent treatment guidelines recommending ART use for all HIV-infected individuals, regardless of CD4+ T-cell (CD4+) count. [11] This represents a profound departure from prior practices that used CD4+ count thresholds to guide ART initiation, largely due to improved toxicity profiles of modern therapies and data suggesting that sustained HIV suppression and maintenance of T-cell levels are optimal in preventing AIDS and non-AIDS morbidity.
Assessment of carotid artery intima-media thickness (cIMT) has been used to understand the relationship between HIV-related risk factors and subclinical atherosclerosis, both in crosssectional [12, 13] and longitudinal studies. [14, 15] Longitudinal studies have shown mixed results, with some demonstrating increased progression of cIMT by HIV serostatus, [16] and others finding no association. [17, 18] HIV-related factors such as inflammation, [18, 19] nadir CD4+ count, [15, 17] and use of protease inhibitors [14, 15] have been found to affect cIMT progression.
However, many studies have been limited by small samples or study duration. Unanswered questions include whether blood vessel wall characteristics in different carotid artery regions may be differentially affected by HIV infection, [19] whether unmeasured confounders explain reported differences between HIV-infected and uninfected study populations, [20] and whether long-term HIV suppressive therapy has pro-atherogenic effects.
A c c e p t e d M a n u s c r i p t 5 In a cross-sectional analysis of two large cohorts of HIV-infected and uninfected individuals, we previously identified an increased prevalence of subclinical carotid artery atherosclerosis among HIV-infected persons, particularly in those with CD4+ counts <200 cells/μL. [21] We now report on the association of HIV infection with progression of subclinical atherosclerosis, after following this same well-characterized population over seven years.
METHODS

Study setting, selection, and inclusion criteria.
Participants were from two longstanding prospective multicenter cohort studies of individuals with or at risk for HIV infection: the Women's Interagency HIV Study (WIHS) and the Multicenter AIDS Cohort Study (MACS). [22, 23] Details on study design are in the Appendix. Briefly, each study has semiannual follow-up visits, during which participants undergo similar detailed examinations and structured interviews. WIHS/MACS participants were recruited to participate in a vascular disease substudy beginning in 2004. The primary exclusion criterion was a history of coronary heart disease. All individuals provided informed consent, and the studies were approved by each IRB.
Data collection.
Data for the current study were collected at a baseline visit occurring between 2004-2006, and at each substudy follow-up visit, occurring every 2-3 years through 2013.
Participants underwent high-resolution B-mode carotid artery ultrasound to image six locations in the right carotid artery according to previous published procedures: [24] the near and far walls of the common carotid artery (CCA), carotid bifurcation, and internal carotid artery (ICA). A standardized protocol was used at all sites, [21] and carotid artery outcome measures were obtained at a centralized reading center (University of Southern California). Coefficients of A c c e p t e d M a n u s c r i p t 6 variation of repeated CCA-IMT measures have been published, [21] and replicate image acquisition and interpretation studies were repeated with each follow-up visit wave to ensure consistency over time. Additional demographic, clinical, and laboratory variables were collected with standardized protocols at semi-annual core study visits.
Main outcome measures.
To assess progression of subclinical atherosclerosis, we examined two carotid artery ultrasound outcome measures. The first was individual change in cIMT from baseline at the far wall of the right CCA (CCA-IMT) over time. The far wall yields the least variability in measurement. Mean CCA-IMT at each visit was assessed from standardized ultrasound images by automated computerized edge detection. [25] Participants contributed up to 3 additional CCA-IMT measures after baseline for change assessment (Figure 1) .
The second outcome was new focal plaque formation, defined as a dichotomous increase in the number of focal plaques measured over the six carotid artery locations between the baseline and final vascular study visit. We defined a plaque, or lesion, as an area with localized IMT >1.5 mm. [26] Because plaques were only assessed at two visits, sample size for this outcome (N=1,313) was smaller than for CCA-IMT change (N=1,822).
HIV exposure and other variables.
HIV infection was ascertained using serologic testing (ELISA) and confirmed using Western blot. Self-reported variables included age, race/ethnicity, income, education, history of injection drug use, and current crack/cocaine and alcohol use.
Hepatitis C virus infection status was based on antibody or viral RNA testing. Cardiometabolic risk factors included body mass index (BMI), systolic blood pressure, total and high-density lipoprotein cholesterol, and the following self-reported variables: current cigarette smoking, current use of antihypertensive and lipid-lowering medications, and history of diabetes mellitus.
A c c e p t e d M a n u s c r i p t baseline vascular study visit.
We defined persistent virologic suppression as consistent plasma HIV RNA (viral load) levels <80 copies/mL (WIHS) or <50 copies/mL (MACS) during the period between the first and last vascular substudy visits (up to 16 measurements per participant). Persons continuously receiving ART with consistently suppressed viral loads were considered "persistently suppressed". We allowed for one virologic "blip" during the period as long as it was <500 copies/mL, based on evidence that blips ≥500 copies/mL are associated with virologic rebound. [27] Participants were allowed to miss no more than one core visit to be eligible for being categorized as "persistently virologically suppressed". All models were first developed within each cohort. After comparing directionality of associations, we combined cohorts, since results were qualitatively similar. We confirmed the validity of combining cohorts by assessing cohort-covariate interaction terms. No terms were statistically significant.
Further analyses examined longitudinal change in subclinical atherosclerosis in key HIVinfected subsets. The first examined whether ART-treated and persistently suppressed HIVinfected participants had decreased progression of carotid artery disease, versus comparison groups of: 1) all other HIV-infected participants and; 2) HIV-uninfected participants. In a sensitivity analysis, we created an alternate definition of persistent HIV suppression that did not require consistent ART use, which would also include elite controllers. A second analysis examined HIV-infected groups defined by CD4+ count at entry into the vascular substudy. The comparisons of interest were the HIV-infected group with CD4+ counts in the normal range (≥500 cells/μL), versus 1) HIV-infected individuals with lower CD4+ counts, and 2) HIVuninfected participants. Finally, among HIV-infected participants, we assessed the impact on carotid artery ultrasound parameters of cumulative duration of ART use (overall and by drug class), history of clinical AIDS, and nadir CD4+ count.
Analyses were conducted using SAS 9.3 and R 3.0.2. We determined statistical significance by a two-sided P-value <0.05. We used multiple imputation (5 datasets) based on multivariate sequential regression to account for the 7% of participants with missing data for a few covariates. [28] M a n u s c r i p t 9
RESULTS
Participant characteristics. There were 1,011 women (74% HIV-infected) and 811 men (65% HIV-infected) who met study inclusion criteria and had at least two vascular substudy visits.
Median follow-up time (years) was 6.5 for women and 7 for men, corresponding to 4 and 3 vascular assessments. Baseline characteristics are shown in Table 1 . Median age (years) was 40 in women and 49 in men. Women were more likely to be of black race or Hispanic ethnicity than men (89% versus 35%). At baseline, women were more likely to report current cigarette smoking (47% versus 30%) and have higher BMI (median 28.2 versus 25.4 kg/m 2 ) than men.
Men had higher systolic blood pressures (124 versus 116 mmHg) and total cholesterol levels (194 versus 172 mg/dL), and were more likely to be current users of anti-hypertensive (23% versus 18%) or lipid-lowering medications (24% versus 5%). HIV-infected and uninfected participants were generally similar, although HIV-infected participants were more likely to have previously injected drugs and be co-infected with HCV. The majority of HIV-infected individuals reported using ART at baseline (67% among women; 76% among men).
Predictors of CCA-IMT increase: HIV serostatus and CVD risk factors. HIV infection was
not associated with the magnitude of CCA-IMT increase over time (Figure 1) . Multivariable models adjusting for demographic, behavioral, and cardiometabolic risk factors showed no significant difference in CCA-IMT change by HIV serostatus (adjusted β=0.2 µm/year higher in HIV-infected persons, 95% CI -0.6-1.0). Statistically significant predictors of CCA-IMT increase in multivariable analyses included black race, Hispanic ethnicity, and crack/cocaine use (Appendix Table 1 ). Use of antihypertensive medications was associated with a decrease in
CCA-IMT.
A c c e p t e d M a n u s c r i p t 10 Figure 2 shows the presence of focal carotid artery plaques at the baseline and last vascular substudy visits by HIV serostatus. Plaques were more common among the older men (24% with at least one plaque at baseline and 34% at the last visit) than the younger women (8% and 15%). The older men were also more likely to have an increase over time in number of plaques (22% versus 11%). Focal plaque was more commonly observed at the carotid artery bifurcation compared with the ICA, and least commonly observed at the CCA.
Predictors of new focal plaque formation: HIV serostatus and CVD risk factors.
HIV infection was associated with an unadjusted 66% increase in new focal plaque formation (relative risk [RR] 1.66, 95% CI 1.18-2.34) ( Table 2) . After adjusting for demographic, behavioral, and cardiometabolic risk factors, this association remained significant (adjusted RR
[aRR] 1.61, 95% CI 1.12-2.32). Similar associations were observed among males (aRR 1.65, 95% CI 1.03-2.66) and females (aRR 1.53, 95% CI 0.85-2.76). A sensitivity analysis among participants without preexisting lesions showed similar results: a 59% increase in new focal plaque formation among HIV-infected individuals relative to uninfected individuals (95% CI 1.04-2.43). Current smoking was associated with a 42% increase in focal plaque formation (95% CI 1.03-1.96) ( Table 3) . Other associated factors in fully-adjusted analyses included use of antihypertensive medications, higher total cholesterol, and older age.
HIV-infected participants with persistent virologic suppression.
We identified 199 HIVinfected participants who were receiving ART and persistently virologically suppressed (16% of HIV-infected women, N=92; 29% of HIV-infected men, N=107) ( Table 4 and Appendix Table   2 ). Among this selected group, increased risk of new focal plaque formation compared with the HIV-uninfected group remained (aRR 1.77, 95% CI 1.13-2.77). Additional analyses using an alternate definition of persistent virologic suppression or limited to individuals without preexisting A c c e p t e d M a n u s c r i p t 11 lesions did not alter this finding. No associations were found between persistent virologic suppression and CCA-IMT progression, compared with uninfected individuals.
HIV-infected participants with higher CD4+ counts. HIV-infected participants with CD4+
counts ≥500 cells/μL at baseline had a risk of new focal plaque formation that was not statistically different from HIV-uninfected participants (aRR 1.28, 95% CI 0.85-1.94). HIVinfected participants with the lowest CD4+ count at baseline (i.e., <200 cells/μL) had the greatest risk (aRR 2.57, 95% CI 1.48-4.46) compared with HIV-uninfected participants, with a gradient of decreasing risk by increasing categories of CD4+ count ( Table 4 ).
Other HIV-related predictors. Our analyses did not find any association of nadir CD4+ count, history of AIDS, and duration of ART use with new focal plaque formation. We found a slightly increased risk of plaque formation with greater exposure to protease inhibitors among men (aRR 1.12 per year of cumulative use at baseline, 95% CI 1.01-1.25) but not among women.
No other associations between other ART classes and focal plaque formation were found, nor were any HIV-related parameters associated with increased CCA-IMT progression (Appendix Table 3 ).
DISCUSSION
Using non-invasive carotid B-mode ultrasonography, we demonstrated that HIV-infected women and men had a 61% greater risk of new focal carotid artery plaque formation over seven years compared with uninfected controls, regardless of baseline vascular phenotype and after controlling for cardiometabolic risk factors. The HIV-associated risk was higher than that associated with smoking. Furthermore, the elevated risk persisted among ART-treated individuals with persistent HIV viral suppression, suggesting that sustained suppression of Our findings are consistent with a growing body of evidence linking HIV infection with CVD. To our knowledge, our study is the largest and longest examining whether HIV infection is associated with incidence and progression of subclinical carotid atherosclerosis, with >1,800 study participants recruited across 10 U.S. locations. By design, our comparison group of HIVuninfected participants had similar sociodemographic and behavioral characteristics as participants with HIV infection. This is a major strength, given the well-known threats to validity when making comparisons of age-related disease outcomes that may stem from health behaviors (e.g., drug use, smoking) in HIV-infected individuals that differ from those in the general population. [20] We did not find differences in CCA-IMT progression over the seven years by HIV serostatus, consistent with smaller studies. [17, 18] Moreover, prior studies that have measured several carotid artery segments have found that IMT in the internal carotid artery and carotid bifurcation have been more consistently associated with HIV infection than CCA-IMT. [16, 19] The increased rate of plaque progression in disease-prone segments of the carotid arterial tree that we found among HIV-infected participants corroborates these previous findings. Collectively, these findings add strong support to the hypothesis that development of atherosclerosis in HIVinfected individuals involves endothelial shear stress preferentially occurring at vascular branch points, [19] which may represent a common pathway with atherosclerosis arising from other conditions such as rheumatoid arthritis. [29] M a n u s c r i p t 13 While HIV infection was the factor most strongly associated with formation of new focal plaque, elevated risk was seen with smoking and increased total cholesterol levels, both of which are amenable to modification. [30] Over one-third of our HIV-infected participants were current smokers. Thus, our findings, consistent with other studies among both HIV-infected individuals and the general population, [15, 31] support recommendations promoting smoking cessation for HIV-infected individuals. [32] Use of antihypertensive medications appeared to be associated with decreased CCA-IMT progression but increased plaque. While antihypertensive medication through its effects on blood pressure may reduce wall hypertrophy in the CCA, [33] it may not reduce or correct turbulent blood flow, so it may appear as though such medications associate with plaque formation. Most of the plaque we detected was found in the bifurcation and ICA segments, which are affected more by turbulent flow, supporting this premise. Alternatively, antihypertensive medication could serve as a marker for longstanding hypertension that has led to plaque formation.
Our finding that participants who maintained HIV suppression still had an increased risk of new focal plaque formation suggests that vigilance with respect to the long-term adverse consequences of ART remains warranted for all HIV-infected individuals. This elevated risk may be due in part to low-level HIV replication and inflammation that persists despite reductions in viral load. [10, 34, 35] Future work should confirm our findings and further explore the extent to which these factors play a role in CVD development.
A c c e p t e d M a n u s c r i p t 14 We found a slightly elevated association between exposure to protease inhibitors and new focal plaque formation among men but not women, consistent with our cross-sectional findings. [21] Concerns about protease inhibitor use initially arose based on data from the D:A:D Study, in which an elevated risk of myocardial infarction among protease inhibitor users was observed. [8] Given the small magnitude of our effect estimate (aRR 1.12 per year of cumulative use) and improvements in risk profiles of available ART drugs since this study was initiated, our finding should be interpreted with caution. The overwhelming benefits of ART should not be minimized, since participants with CD4+ counts in the normal range (≥500 cells/μL) had atherosclerotic risks similar to HIV-uninfected participants. In fact, CD4+ count was the single HIV-related factor conferring a linear, monotonic risk of plaque formation, supporting treatment guidelines that advocate early ART initiation, allowing for better CD4+ maintenance.
Our study has limitations. First, only the right carotid artery was examined; however, other studies have found wall thickness to be correlated bilaterally.
[37] Second, the use of long-term cohort studies may induce selection bias, and some participants were not able to attend all vascular study visits. However, we do not have a strong basis to believe that inferences would change as a result (Appendix). Furthermore, the women and men in our study have the same age distribution as the U.S. HIV-infected population, [22, 38] supporting the generalizability of our results. We carefully adjusted for many established confounders, including cardiometabolic risk factors, but did not have comprehensive data on diet, physical activity, and other lifestyle factors and therefore cannot rule out the possibility of unmeasured confounding. We used carotid More HIV-infected individuals are initiating ART earlier in the course of their infection, with concomitant improvements in long-term virologic control. [41] Our data support earlier ART initiation, before CD4+ counts decline, which may mitigate HIV-associated increased CVD risks.
Better understanding of these processes is necessary, both to prevent or delay CVD development and to improve treatment strategies in the growing and increasingly older HIVinfected population. M a n u s c r i p t 28 A c c e p t e d M a n u s c r i p t a Persistently suppressed viral load (<50 copies/mL for MACS, <80 copies/mL for WIHS) and consistently on ART throughout study period. b P for trend.
HIV-specific characteristics
All analyses control for age, race/ethnicity, education, income, study site, history of injection drug use, crack/cocaine use, current smoking, current alcohol use, history of hepatitis C infection, body mass index, systolic blood pressure, total and HDL cholesterol, use of anti-hypertension medications, use of anti-cholesterol medications, history of diabetes. All models (except persistent suppression model) also control for history of AIDS. Counts are prior to multiple imputation. 
